Home
Live Updates
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study : comparemela.com
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study
/PRNewswire/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that data from the previously announce Study '098 demonstrated...
Related Keywords
Massachusetts ,
United States ,
Delaware ,
Matthew Duffy ,
Mark Poznansky ,
James Ahern ,
Patrickj Gallagher ,
Patrick Gallagher ,
Exchange Commission ,
Prnewswire Voltron Therapeutics Inc ,
Voltron Therapeutics Inc ,
Immunotherapy Center ,
Lucius Partners ,
Laidlaw Company United Kingdom ,
Massachusetts General Hospital ,
Overall Survival ,
Proof Of Concept ,
Self Assembling Vaccine ,
Primary Endpoint ,
Chief Executive Officer ,
Managing Partner ,
United Kingdom ,
Voltron Therapeutics ,
Emerging Infectious ,
Lassa Fever ,
Private Securities Litigation Reform Act ,
Vaxcelerate Platform ,
comparemela.com © 2020. All Rights Reserved.